Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels - Full Text View

Sponsor:	GlaxoSmithKline
Information provided by:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT00062790

Purpose

This study is being done to determine how much certain hormone levels in the prostate decrease when a patient takes dutasteride 0.5mg daily for 3 months prior to TURP. Male patients at least 50 years old willing to take either dutasteride or a placebo (dummy pill) once daily by mouth for 3 months prior to having a surgery to reduce the size of their prostate. During the surgery, very small pieces of the prostate that are removed will be tested to see how much dihydrotestosterone and testosterone (male hormones) are in the tissue.

Condition	Intervention	Phase
Benign Prostatic Hyperplasia	Drug: Dutasteride	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Parallel Assignment, Pharmacokinetics/Dynamics Study
Official Title:	Effects of Dutasteride on Intraprostatic Dihydrotestosterone (DHT) Levels

Resource links provided by NLM:

Drug Information available for: Dihydrotachysterol Dutasteride Stanolone

U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:

Effect of repeat oral daily dosing of 0.5mg dutasteride compared to placebo on prostate tissue content of DHT in patients treated for 3 months prior to transurethral resection of the prostate (TURP).

Secondary Outcome Measures:

Effect of repeat oral once daily dosing of 0.5mg dutasteride compared to placebo on prostatic tissue content of testosterone.
Changes in serum DHT (dihydrotestosterone) and T (testosterone).

Estimated Enrollment:	50
Study Start Date:	October 2003

Eligibility

Ages Eligible for Study:	50 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria:

Diagnosed with benign prostatic hyperplasia
Must be scheduled to have a transurethral resection of the prostate (prostate surgery) and be able to wait 3 months to have the procedure.
PSA (prostate specific antigen) level must be between 1.5 and 15 ng/ml.

Exclusion criteria:

Prostate cancer.
Use of saw palmetto or other over the counter treatments for prostate health chemically related to the study medication.
Previous finasteride use or other investigational 5ARI within 6 months prior to screening.
History of chronic UTIs (urinary tract infections)
Presence of acute bacterial prostatitis at screening

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00062790

Locations

United States, California
GSK Investigational Site
Long Beach, California, United States, 90806
United States, Connecticut
GSK Investigational Site
New Britain, Connecticut, United States, 06052
GSK Investigational Site
Trumbull, Connecticut, United States, 06611
United States, Georgia
GSK Investigational Site
Augusta, Georgia, United States, 30912
United States, Illinois
GSK Investigational Site
Niles, Illinois, United States, 60714
GSK Investigational Site
Chicago, Illinois, United States, 60612
United States, New Hampshire
GSK Investigational Site
Lebanon, New Hampshire, United States, 03756
United States, Oregon
GSK Investigational Site
Eugene, Oregon, United States, 97401-8122
United States, Texas
GSK Investigational Site
Dallas, Texas, United States, 75235
United States, Virginia
GSK Investigational Site
Richmond, Virginia, United States, 23249

Sponsors and Collaborators

GlaxoSmithKline

Investigators

Study Director:

GSK Clinical Trials, MD

GlaxoSmithKline

More Information

No publications provided

Responsible Party:	GSK ( Study Director )
Study ID Numbers:	ARI40014
Study First Received:	June 16, 2003
Last Updated:	October 13, 2008
ClinicalTrials.gov Identifier:	NCT00062790 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:

DHT
TURP
Testosterone

Additional relevant MeSH terms:

Molecular Mechanisms of Pharmacological Action
Prostatic Diseases
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Enzyme Inhibitors
Genital Diseases, Male
Hormones

Pharmacologic Actions
Dutasteride
Hyperplasia
Pathologic Processes
Prostatic Hyperplasia
Dihydrotestosterone
Androgens

ClinicalTrials.gov processed this record on November 27, 2009